A single daily pill slashed “bad” cholesterol by 60% in high-risk patients, rivaling pricey injections without needles—could this end heart disease’s reign as America’s silent killer?
Story Highlights
- Enlicitide, an oral pill from Merck, cut LDL cholesterol by 60% when added to statins in a 2,900-patient phase 3 trial published in the New England Journal of Medicine.
- Effects lasted a full year with no major safety issues, targeting patients who fail max statin therapy.
- FDA fast-track review underway; positions as convenient alternative to injectable PCSK9 drugs.
- Experts hail it as the most effective oral LDL reducer since statins, but await outcomes trial for heart event proof.
Phase 3 Trial Delivers Breakthrough LDL Reduction
Merck’s enlicitide enrolled 2,909 high-risk patients with atherosclerosis or related conditions in a randomized phase 3 trial. Researchers added the oral pill or placebo to standard statin therapy. At 24 weeks, enlicitide reduced LDL cholesterol by 60%, plus drops in non-HDL, apoB, and Lp(a). Benefits held steady through 52 weeks. Patients took it on an empty stomach daily. No significant safety differences emerged versus placebo.
PCSK9 Inhibition Goes Oral After Injectable Era
High LDL cholesterol fuels plaque buildup, driving U.S. heart disease deaths. Statins like Lipitor block liver production but leave half of high-risk patients above 70 mg/dL targets. PCSK9 protein curbs liver LDL clearance; genetics linked its scarcity to low cholesterol. Injectables like evolocumab achieved 60% reductions post-2015 but faced adherence issues from cost, complexity, and aversion. Enlicitide orally inhibits PCSK9, matching efficacy without shots.
Stakeholders Drive Momentum Toward Approval
Dr. Ann Marie Navar at UT Southwestern led the trial, stressing its real-world match to practice. Merck funded the study and a larger 14,000-patient outcomes trial testing heart attacks and strokes. UT Southwestern, a lipid research powerhouse, hosted sites. FDA granted fast-track status using phase 3 data. Independent expert Dr. William Boden praised LDL evidence but flagged the outcomes data gap. Merck’s independence and NEJM peer review counter funding bias concerns.
Navar called enlicitide the strongest oral LDL cutter since statins, poised for population-wide prevention.
Short-Term Gains and Long-Term Promise
Short-term, enlicitide boosts adherence for statin users needing more control, with FDA approval eyed for 2026-2027. Long-term, positive outcomes data could slash cardiovascular events and reshape guidelines. High-risk patients gain easiest access yet. Merck eyes revenue while cutting system costs from prevented events. Industry shifts from injectables spurs oral competition, advancing lipid science.
Uniform expert praise covers LDL data and safety; the empty-stomach rule poses minimal hurdle. Outcomes trial results will confirm if 60% drops translate to fewer heart attacks, addressing the key uncertainty.
Sources:
Cholesterol Levels Slashed by 60% in Promising New Pill Trial
Experimental pill dramatically reduces ‘bad’ cholesterol
Experimental pill slashes bad cholesterol levels
New oral pill could improve cholesterol control for people at risk of heart attack, study says
New Pill Slashes Bad Cholesterol by 60%
